Login / Signup

Risk-Adapted Preemptive Tocilizumab to Prevent Severe Cytokine Release Syndrome After CTL019 for Pediatric B-Cell Acute Lymphoblastic Leukemia: A Prospective Clinical Trial.

Stephan KadaukeRegina M MyersYimei LiRichard AplencDiane BaniewiczDavid M BarrettAllison Barz LeahyColleen CallahanJ Gregory DolanJulie C FitzgeraldWhitney GladneySimon F LaceyHongyan LiuShannon L MaudeRegina McGuireLaura S MotleyDavid Trent TeacheyGerald B WertheimLisa WrayAmanda M DiNofiaStephan A Grupp
Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
Risk-adapted PT administration resulted in a decrease in the expected incidence of grade 4 CRS, meeting the study end point, without adversely impacting the antitumor efficacy or safety of CTL019.
Keyphrases